FUTURE AJANTA PHARMA History

2005
-Max Healthcare to establish India`s first brain lab in New Delhi
-Max India Ltd Max telecom ventures Ltd signed a MoU

2008
-Max India signs agreement with UK firm for health insurance biz

2012
-Board declares Interim Dividend of 500% i.e. Rs. 10/- for every equity share of Rs. 2/- each to the shareholders.
-Ajanta Pharma Ltd has splits its face value from Rs 10/- to 5/-


2013
- Board recommends Final Dividend 610% amounting to Rs. 12.20 per equity share of Rs. 2/- each to the shareholders.
-Ajanta Pharma has announces bonus in the ratio of 1:2

2014
-Board recommends Final Dividendof 90%, i.e., Rs. 1.80 for every equity share of Rs. 2/- each to the shareholders

2015
-Ajanta Pharma Announces the Launch of Montelukast Sodium Oral Granules
-Launch of Montelukast lR Tablets and Montelukast Chewable Tablets in US market
-Fortune India presents award to Ajanta Pharma
-Ajanta Pharma gets approvals for 3 ANDA''s
-Ajanta Pharma has splits its face value from Rs. 5 to Rs. 2




CIN: U67190WB2003PTC096617. Trading in Commodities is done through our Group Company Dynamic Commodities Pvt. Ltd. The company is also engaged in Proprietory Trading apart from Client Business.
“2019 © COPYRIGHT DYNAMIC EQUITIES PVT. LTD.”

Disclaimer: There is no guarantee of profits or no exceptions from losses. The investment advice provided are solely the personal views of the research team. You are advised to rely on your own judgment while making investment / Trading decisions. Past performance is not an indicator of future returns. Investment is subject to market risks. You should read and understand the Risk Disclosure Documents before trading/Investing.

Disclosure: We, Dynamic Equities Private Limited are also engaged in Proprietory Trading apart from Client Business. In case of any complaints/grievances, clients may write to us at compliance@dynamiclevels.com

  • Download our Mobile App
  • Available on Google Play
  • Available on App Store
  • RSS